Bosulif (bosutinib) — Medica
Acute lymphoblastic leukemia (Philadelphia chromosome-positive)
Initial criteria
- age ≥ 15 years
- Patient has Philadelphia chromosome-positive acute lymphoblastic leukemia
- Patient has tried at least one other tyrosine kinase inhibitor for Philadelphia chromosome-positive acute lymphoblastic leukemia (e.g., imatinib or dasatinib)
Approval duration
1 year